The American-owned Kimberly-Clark Australia Millicent Mill increased its production of tissue products by an unspecified amount in the last calendar year.
The Kimberly-Clark Corporation released its annual results to the New York Stock Exchange at 10pm on Tuesday night.
This was the only reference to Australia in the document.
KCC chief executive and chairman Mike Hsu announced the fourth quarter and full year 2024 results and his remarks had an upbeat tone.
He said the results illustrated the strength of its innovation-led growth model, driving volume gains, improving product mix, and generating significant efficiencies enabling reinvestment in its brands, new capabilities, and generating attractive returns to its shareholders.
“2024 was a breakthrough year for Kimberly-Clark with the launch of our transformative, multi-year Powering Care strategy and successfully rewiring our organization into three powerhouse segments with world-class functional support,” Mr Hsu said.
“Our full-year results exceeded our new long-term growth algorithm – supported by consistent execution across the organisation – and we established a strong foundation to accelerate our strategy in 2025 and beyond.
“We delivered organic top-line growth with an upward inflection in volume-plus-mix.
“This, coupled with improved productivity, has driven strong adjusted profit growth and fuelled investments to advance our competitive advantage.
“We’re excited about this new chapter of Kimberly-Clark, and we look forward to building on our momentum and enhancing value for all stakeholders.”
As per company policy, the financial results of KCA and other individual countries were not stated.
Major Kimberly-Clark Corporation operational decisions are often announced at this time.
Mr Hsu is due to attend a press conference scheduled for this morning (South Australian time).
Last week, the Millicent Mill was inspected by Supply chain manager Ganesh Krishnamurthy who is based at the Kimberly-Clark Corporation Asia Pacific headquarters in Singapore.